Literature DB >> 10695644

Antipsychotic drug treatment in first-episode mania: a 6-month longitudinal study.

C A Zarate1, M Tohen.   

Abstract

OBJECTIVE: To determine the use of antipsychotics during and following inpatient treatment of patients with a first-episode of mania.
METHOD: The 198 subjects available for analysis were 129 consecutively hospitalized first-episode manic patients and 69 nonaffective psychotic patients assessed at admission and at 6-month follow-up postdischarge. Comparisons between the groups were made on frequency, type, and doses of antipsychotics prescribed during and after hospitalization in relation to clinical status.
RESULTS: First-episode manic patients were given lower mean +/- SD daily doses of antipsychotics than nonaffective psychotic patients at discharge (163 +/- 132 mg chlorpromazine equivalents [CPZe] vs. 224 +/- 167 mg CPZe, p = .0102), at 6-month follow-up (109 +/- 167 mg CPZe vs. 260 +/- 178 mg CPZe; p = .0001), and if recovered (110 +/- 174 mg CPZe vs. 265 +/- 207 mg CPZe, p = .0014). At 6-month follow-up, 31 (24%) of 129 manic and 24 (35%) of 69 nonaffective psychotic patients continued to receive antipsychotics (NS). There was no difference between the groups in the time to discontinuation of antipsychotic agents. The mean time to drug discontinuation in manic patients was 98 days.
CONCLUSION: (1) Antipsychotic doses at discharge and at 6-month follow-up were much lower in manic than in nonaffective psychotic patients, although there was no significant difference in the proportion of patients who continued to receive them 6 months after discharge. (2) The time to discontinuation was independent of clinical outcome. In those who discontinued the antipsychotic agent, the time to discontinuation was more rapid in the manic group than in the nonaffective psychotic patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10695644     DOI: 10.4088/jcp.v61n0109

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  4 in total

Review 1.  Functional impairment and cognition in bipolar disorder.

Authors:  C A Zarate; M Tohen; M Land; S Cavanagh
Journal:  Psychiatr Q       Date:  2000

Review 2.  Atypical antipsychotics and mood stabilization in bipolar disorder.

Authors:  Paolo Brambilla; Francesco Barale; Jair C Soares
Journal:  Psychopharmacology (Berl)       Date:  2003-02-27       Impact factor: 4.530

Review 3.  Cellular mechanisms underlying affective resiliency: the role of glucocorticoid receptor- and mitochondrially-mediated plasticity.

Authors:  Joshua G Hunsberger; Daniel R Austin; Guang Chen; Husseini K Manji
Journal:  Brain Res       Date:  2009-07-10       Impact factor: 3.252

Review 4.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.